Eravacycline (TP-434) Is Efficacious in Animal Models of Infection
Open Access
- 1 May 2015
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (5) , 2567-2571
Abstract
Eravacycline is a novel broad-spectrum fluorocycline antibiotic being developed for a wide range of serious infections. Eravacycline was efficacious in mouse septicemia models, demonstrating 50% protective dose (PD 50 ) values of ≤1 mg/kg of body weight once a day (q.d.) against Staphylococcus aureus , including tetracycline-resistant isolates of methicillin-resistant S. aureus (MRSA), and Streptococcus pyogenes . The PD 50 values against Escherichia coli isolates were 1.2 to 4.4 mg/kg q.d. In neutropenic mouse thigh infection models with methicillin-sensitive S. aureus (MSSA) and S. pyogenes , eravacycline produced 2 log 10 reductions in CFU at single intravenous (i.v.) doses ranging from 0.2 to 9.5 mg/kg. In a neutropenic mouse lung infection model, eravacycline administered i.v. at 10 mg/kg twice a day (b.i.d.) reduced the level of tetracycline-resistant MRSA in the lung equivalent to that of linezolid given orally (p.o.) at 30 mg/kg b.i.d. At i.v. doses of 3 to 12 mg/kg b.i.d., eravacycline was more efficacious against tetracycline-resistant Streptococcus pneumoniae in a neutropenic lung infection model than linezolid p.o. at 30 mg/kg b.i.d. Eravacycline showed good efficacy at 2 to 10 mg/kg i.v. b.i.d., producing up to a 4.6 log 10 CFU reduction in kidney bacterial burden in a model challenged with a uropathogenic E. coli isolate. Eravacycline was active in multiple murine models of infection against clinically important Gram-positive and Gram-negative pathogens.Keywords
This publication has 11 references indexed in Scilit:
- Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal InfectionsAntimicrobial Agents and Chemotherapy, 2014
- Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community PathogensAntimicrobial Agents and Chemotherapy, 2013
- Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline AntibioticAntimicrobial Agents and Chemotherapy, 2012
- Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial AgentJournal of Medicinal Chemistry, 2012
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020Clinical Infectious Diseases, 2010
- Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic StewardshipClinical Infectious Diseases, 2009
- Prevalence and Risk Factor Analysis of Trimethoprim‐Sulfamethoxazole– and Fluoroquinolone‐ResistantEscherichia coliInfection among Emergency Department Patients with PyelonephritisClinical Infectious Diseases, 2008
- Editorial Commentary:Finding the Path of Least Antimicrobial Resistance in PyelonephritisClinical Infectious Diseases, 2008
- Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPEThe Journal of Infectious Diseases, 2008